Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?
Cells · 12.08.2025 · 14 (16) · 1242
DOI: 10.3390/cells14161242 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 12.08.2025. Verfasst von Panagiota Anyfanti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Rheumatic Diseases, Autoimmune Diseases, Immunotherapy, Adoptive. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell immunotherapy has changed the landscape of B cell hematological malignancies’ management, while it has recently shown promising results in the treatment of refractory autoimmune rheumatic disorders (ARDs). Targeting B cell antigens such as CD19 and BCMA, CAR-T cell therapy can induce sustained remission by the elimination of autoreactive B cell populations resistant to the standard of care treatment options. Clinical data from case reports and small case series demonstrate profound clinical responses in ARDs, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs), rheumatoid arthritis (RA), antiphospholipid syndrome (APS), and primary Sjögren’s syndrome (pSS). Treatment outcomes include reduced disease activity, normalization of serologic markers, improved organ function, and drug-free remission, even after B cell reconstitution. Additionally, toxicities, primarily limited to mild cytokine release syndrome (CRS), were generally manageable with supportive care. Encouraging preliminary results have led to the development of several ongoing clinical trials investigating CAR-T cell therapy across multiple ARDs and patient populations, including pediatric patients. This review summarizes the current clinical experience and provides a comprehensive overview of ongoing clinical trials exploring CAR-T cell immunotherapy for ARDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Second Propaedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
- Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
- Hematology Department, BMT Unit, General Hospital "George Papanicolaou", 57010 Thessaloniki, Greece.
- Fourth Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Panagiota Anyfanti, Paschalis Evangelidis, Nikolaos Kotsiou, Anna Papakonstantinou, Theodoros Dimitroulas, Eleni Gavriilaki
Zitieren
APA
Anyfanti, P., Evangelidis, P., Kotsiou, N., Papakonstantinou, A., Eftychidis, I., Sakellari, I., Dimitroulas, T., & Gavriilaki, E. (2025). Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?. Cells, 14(16), 1242. https://doi.org/10.3390/cells14161242
Vancouver
Anyfanti P, Evangelidis P, Kotsiou N, Papakonstantinou A, Eftychidis I, Sakellari I, et al. Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?. Cells. 2025;14(16):1242. doi:10.3390/cells14161242
BibTeX
@article{Anyfanti2025,
author = {Anyfanti, Panagiota and Evangelidis, Paschalis and Kotsiou, Nikolaos and Papakonstantinou, Anna and Eftychidis, Ioannis and Sakellari, Ioanna and Dimitroulas, Theodoros and Gavriilaki, Eleni},
title = {Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?},
journal = {Cells},
year = {2025},
volume = {14},
number = {16},
pages = {1242},
doi = {10.3390/cells14161242}
}
EUVIMED